NPPA show cause notice over Symbicort Turbuhaler pricing

Regulatory & Legal View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹9083.50

prior close

₹9007.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-0.7% vs market

Pharmaceuticals peers, median of 152sector-0.0%-0.8% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

-0.0

15m

-0.0

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.1-0.7-0.0-0.8

Next day

-1.0+0.7-1.6-0.2-0.8

-0.8+1.2-2.0+0.1-0.9

+0.2+1.9-1.7+0.0+0.2

+0.1+1.6-1.6+0.4-0.3

-1.4+2.0-3.4+0.1-1.5

-3.5+0.9-4.5-0.6-2.9

15d

+3.2-1.4+4.7-3.0+6.3

+1.5-1.6+3.1-3.7+5.2

+2.0-0.7+2.7-4.3+6.4

+0.8-6.0+6.7-7.5+8.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

India's drug pricing authority alleges that AstraZeneca overcharged for Symbicort Turbuhaler 60-dose batches between April 2016 and July 2025. The notice seeks Rs 60.49 crore plus interest and gives the company 30 days to respond. The company disputes the claim, and the final financial impact is not yet known.

Likely market impact

The disputed claim creates potential financial exposure and uncertainty, but no penalty has been confirmed and the final amount remains undetermined.